Hoppa till huvudinnehållet

Cecilia Williams

Profilbild av Cecilia Williams



Tomtebodavägen 23A, Solna

Om mig

Name of group:Experimental Oncology

Additional position: Visiting Professor, Dept. of Biosciences and Nutrition, Karolinska Institutet

Short description of research:
The research focuses on understanding key molecular mechanisms in cancer, using a combination of large-scale omic approaches, focused mechanistic experiments andin vivo studies. The goal is to understand critical cancer pathways so that we can suggest better cancer treatments and preventive approaches and biomarkers to be tested and developed for clinical use.

The hormone estrogen can increase the risk of breast cancer, while simultaneously protect against colon cancer. It is not understood exactly how, but if we can achieve a detailed knowledge of this mechanism, we would be able to design approaches that can protect against colon cancer while not promoting breast cancer, and we could also improve the treatment of breast cancer. Estrogenic signaling is mediated by the estrogen receptors, ERalpha and ERbeta. They are ligand-activated nuclear receptors and as such excellent therapeutic targets. My research focuses on the estrogen-induced pathways in breast and colon cancer, and the impact that environmental or dietary estrogenic exposure may have.

Related to this, is the identification of molecular mechanisms involving microRNAs and long non-coding RNAs, molecules with great potential as novel biomarkers and therapeutic targets. These molecules are, to various extents, regulated by the estrogen receptors and are likely to contribute to the estrogenic effects, but also, they appear to have key roles in the metastatic capacity of cancer cells. The roles of non-coding RNA in this respect are central to reveal, as a cancer cell’s capacity to set metastasis is the ominous ability that can determine the prognosis of this disease.

Research projects:
Prevention of colorectal cancer through estrogen receptor beta activation (Cancerfonden, PI)

Estrogen-regulated lncRNAs and their tumorsupressive functions in the intestines (VR Swedish Research Council, PI)

Precision pathology - prediction of patient specific drug response (Region Stockholm HMT, co-PI)

QuantumSense - Tunnelströmsdetektion av biomolekyler för snabb avkodning av DNA och RNA (VR Swedish Research Council, forskningsmiljö)

Elucidating the mechanism of ERbeta in colon carcinogenesis (US National Institutes of Health, NIH/NCI, PI:Williams)

Selected publications:

Genome-wide estrogen receptor β chromatin binding in human colon cancer cells reveals its tumor suppressor activity.Indukuri R, Jafferali MH, Song D, Damdimopoulos A, Hases L, Zhao C, Archer A, Williams C.  Int J Cancer  2021 PMID: 33754337.

Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor. Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C, Williams C.   Cancer Lett  2021. PMID: 33652085.

Nuclear receptors: from molecular mechanisms to therapeutics.Frigo DE, Bondesson M, Williams C.  Essays Biochem  2021 PMID: 34825698 (Review)

Intestinal estrogen receptor beta suppresses colon inflammation and tumorigenesis in both sexes. Hases L, Indukuri R, Birgersson M, Nguyen-Vu T, Lozano R, Saxena A, Hartman J, Frasor J, Gustafsson JÅ, Katajisto P, Archer A, Williams C.  Cancer Lett  2020 PMID: 32711097.

Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. Ibrahim A, Hugerth LW, Hases L, Saxena A, Seifert M, Thomas Q, Gustafsson JÅ, Engstrand L, Williams C.  Int J Cancer  2019 PMID: 30515752

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R. (2018)  Cancer Cell  PMID: 29622464

Insufficient antibody validation challenges oestrogen receptor beta research.Andersson S, Sundberg M, Pristovsek N, Ibrahim A, Jonsson P, Katona B, Clausson CM, Zieba A, Ramström M, Söderberg O, Williams C, Asplund A. (2017)  Nature Communications PMID: 28643774

Single-molecule sequencing reveals estrogen-regulated clinically relevant lncRNAs in breast cancer. Jonsson P, Coarfa C, Mesmar F, Raz T, Rajapakshe K, Thompson JF, Gunaratne PH, Williams C. (2015)  Molecular Endocrinology PMID: 26426411

miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. Wang J, Tsouko E, Jonsson P, Bergh J, Hartman J, Aydogdu E, Williams C. (2014)  Molecular Oncology PMID: 25074552


Examensarbete inom kemiteknik, grundnivå (KH138X), examinator | Kurswebb

Kliniska tillämpningar av bioteknik (CB2020), examinator, kursansvarig, lärare | Kurswebb

Kliniska tillämpningar av bioteknik (CB2021), examinator, kursansvarig, lärare | Kurswebb

Profilbild av Cecilia Williams